Article Page

Abstract

A theory elaborated by the author on revised quantum electrodynamics (RQED) is elucidated in a condensed form on special important points. The latter concerns the basic electromagnetic field equations in a vacuum state, the connection of this state with the Zero Point Energy (ZPE), the procedure of quantization, steady states of particle models, the concept of the individual photon, and examples on experimental support of the theory on Some Elucidations of the Theory on Revised Quantum Electrodynamic on Telomerase Peptide Vaccination simulated poly-chemo mimotopic pharmacological structure Combined with Temozolomide as a novel in silico promising anti-cancer drug-like agent in Stage IV Melanoma Patients for structural proteome-wide multi-targeted ligand-binding conserved binding pharmacophoric site comparison.

Keywords

Some Elucidations; Theory on Revised Quantum Electrodynamic; Telomerase Peptide Vaccination; simulated poly-chem mimotopic pharmacological structure Combined with Temozolomide as a novel in silico promising anti-cancer drug-like agent in Stage IV Melanoma Patients for structural proteome-wide multi-targeted ligand-binding conserved binding pharmacophoric site comparison, Quantum Electrodynamics, Zero Point Energy, Standard Model and Beyond.

Article Type

Research Article – Abstract

Publication history

Received: Sep 20, 2017
Accepted: Sep 25, 2017
Published: Oct 01, 2017

Citation

Grigoriadis Ioannis, Grigoriadis George, Grigoriadis Nikolaos, George Galazios (2017) Some Elucidations of the Theory on Revised Quantum Electrodynamic on Telomerase Peptide Vaccination simulated poly-chemo mimotopic pharmacological structure Combined with Temozolomide as a novel in silico promising anti-cancer drug-like agent in Stage IV Melanoma Patients for structural proteome-wide multi-targeted ligand-binding conserved binding pharmacophoric site comparison.

Authors Info

Grigoriadis Nikolaos
Department of IT Computer Aided Personalized Myoncotherapy, Cartigenea-Cardiogenea, Neurogenea-Cellgenea, Cordigenea-HyperoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis Ioannis
Department of Computer Drug Discovery Science, BiogenetoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis George
Department of Stem Cell Bank and ViroGeneaTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

George Galazios
Professor of Obstetrics and Gynecology,
Democritus University of Thrace,
Komotini, Greece;

E-mail: biogeneadrug@gmail.com

File not available